Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
NPJ Breast Cancer|July 27, 2025
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of deathHumaira Noor, Yuanning Zheng, Adam B Mantz, et al.
Cancer|September 17, 2014
Parent decision-making around the genetic testing of children for germline TP53 mutationsMelissa A Alderfer, Kristin Zelley, Robert B Lindell, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2011
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancerDevin Schellenberg, Jeff Kim, Claudia Christman-Skieller, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 30, 2022
The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric CancerAlison F Almeda, Susan M Grimes, HoJoon Lee, et al.
Cancer Discovery|March 15, 2015
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast CancersJohnathan Watkins, Daniel Weekes, Vandna Shah, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 14, 2023
Clinical implications of conflicting variant interpretations in the cancer genetics clinicElyssa Zukin, Julie O Culver, Yuxi Liu, et al.
JAMA|June 14, 2024
Germline CDH1 Variants and Lifetime Cancer RiskCarrie E Ryan, Grace-Ann Fasaye, Amber F Gallanis, et al.
Journal of Medical Genetics|July 19, 2015
Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countriesAva Kwong, Vivian Y Shin, John C W Ho, et al.
JCO Precision Oncology|February 9, 2022
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational StudySteven F Powell, Elie G Dib, Jonathan S Bleeker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Melinda L Telli, Kristin C Jensen, Shaveta Vinayak, et al.
Pageof 19